SCHEMBL11929454

SCHEMBL11929454

Cn1c2cnc(-c3cccnc3)cc2c2c(I)c(F)cnc21

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.43
CYP2E1 P05181 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2B6 P20813 2/20 0.43
CYP2C19 P33261 2/20 0.43
PIM1 P11309 11/20 0.43
PIM3 Q86V86 3/20 0.40
PIM2 Q9P1W9 3/20 0.40
CYP3A4 P08684 2/20 0.39
GRIN1 Q05586 3/20 0.37
GRIN2B Q13224 3/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12435461 0.88 PIM1 (0.46) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL12513172 0.87 PIM1 (0.41) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL12435456 0.87 CYP2A6 (0.43) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL12435501 0.85 NPC1 (0.42) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL12435522 0.82 PIM1 (0.39) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL473708 0.81 CYP2A6 (0.40) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL12435706 0.80 PIM1 (0.38) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL11929453 0.79 CYP2A6 (0.45) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL11929456 0.78 SLC2A1 (0.44) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL12435549 0.77 PDPK1 (0.39) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208809-A1 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-08-16 US disclosed
US-20110178053-A1 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME SANOFI-AVENTIS (FR) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178053-A1 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME AOC3, CBR3, IDH3B CYP2A6 705/4885CYP2E1 1598/4885CYP2C9 681/4885
US-20120208809-A1 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF NPR3, CCNH, CBR3 CYP2A6 1471/4885CYP2E1 1166/4885CYP2C9 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.